Clinical Observation on the Efficacy of Gynecological Tiaojing No.4 Decoction in the Treatment of Perimenopausal Syndrome of Heart-Kidney Disharmony Type

INTERVENTION: Experimental Group:Oral administration of Gynecological Tiaojing No.4 Formula, 1 dose daily, divided into 2 warm doses, continuous treatment for 3 months;Control Group:Oral administration of Climen (Estradiol Valerate/Dienogest Tablets), taken regularly according to the instructions, continuous treatment for 3 months; CONDITION: Perimenopausal Syndrome (Climacteric Syndrome) PRIMARY OUTCOME: Modified Kupperman Index (KI) Score; SECONDARY OUTCOME: Menopause Quality of Life Questionnaire (MEN‐QOL) Score;Pittsburgh Sleep Quality Inde X(PSQI) Score;Self‐rating Anxiety Scale (SAS) Score;Self‐rating Depression Scale (SDS) Score;Polysomnography (PSG) Related Indicators;Heart Rate Variability SDNN (HRV‐SDNN);Serum Se XHormone (E2, LH, FSH) Levels;Serum Inflammatory Factors (IL‐6, TNF‐a) Levels;Serum Neurotransmitter (5‐HT, GABA) Levels;Liver and Renal Function Indicators (ALT, AST, Scr);Adverse Reaction Incidence; INCLUSION CRITERIA: 1.Meeting the integrated traditional Chinese and western medicine diagnostic criteria for perimenopausal syndrome with heart‐kidney imbalance pattern; 2.Females aged 45 to 55 years old; 3.Modified Kupperman Inde X(KI) score = 15 points; 4.Postmenopausal or menstrual disorder with a course of disease > 3 months; 5.No history of hormone replacement therapy in the past 6 months; 6.Good compliance, able to cooperate with the completion of 3‐month treatment and 3‐month follow‐up; 7.Voluntarily sign the informed consent form for clinical research.